Testosterone replacement therapy and vascular thromboembolic events: a systematic review and meta-analysis

Author:

Cannarella Rossella12,Gusmano Carmelo1,Leanza Claudia1,Garofalo Vincenzo1,Crafa Andrea1,Barbagallo Federica1,Condorelli Rosita A1,Vignera Sandro La1,Calogero Aldo E1

Affiliation:

1. Department of Clinical and Experimental Medicine, University of Catania, Catania 95123, Italy

2. Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Abstract

Abstract To evaluate the relationship between testosterone replacement therapy (TRT) and arterial and/or venous thrombosis in patients with pre-treatment total testosterone (TT) <12 nmol l−1, we performed a meta-analysis following the Population Intervention Comparison Outcome model. Population: men with TT <12 nmol l−1 or clear mention of hypogonadism in the inclusion criteria of patients; intervention: TRT; comparison: placebo or no therapy; outcomes: arterial thrombotic events (stroke, myocardial infarction [MI], upper limbs, and lower limbs), VTE (deep vein thrombosis [DVT], portal vein thrombosis, splenic thrombosis, and pulmonary embolism), and mortality. A total of 2423 abstracts were assessed for eligibility. Twenty-four studies, including 14 randomized controlled trials (RCTs), were finally included, with a total of 4027 and 310 288 hypotestosteronemic male patients, from RCTs and from observational studies, respectively. Based on RCT-derived data, TRT did not influence the risk of arterial thrombosis (odds ratio [OR] = 1.27, 95% confidence interval [CI]: 0.47–3.43, P = 0.64), stroke (OR = 1.34, 95% CI: 0.09–18.97, P = 0.83), MI (OR = 0.51, 95% CI: 0.11–2.31, P = 0.39), VTE (OR = 1.42, 95% CI: 0.22–9.03, P = 0.71), pulmonary embolism (OR = 1.38, 95% CI: 0.27–7.04, P = 0.70), and mortality (OR = 0.70, 95% CI: 0.20–2.38, P = 0.56). Meanwhile, when only observational studies are considered, a significant reduction in the risk of developing arterial thrombotic events, MI, venous thromboembolism, and mortality was observed. The risk for DVT remains uncertain, due to the paucity of RCT-based data. TRT in men with TT <12 nmol l−1 is safe from the risk of adverse cardiovascular events. Further studies specifically assessing the risk of DVT in men on TRT are needed.

Publisher

Medknow

Subject

Urology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3